News & Updates

Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Use of metformin with or without liraglutide results in improved glycaemia but falls short of suppressing the high rates of gluconeogenesis in patients with youth-onset type 2 diabetes (Y-T2D), reports a study.